Several glass vials with white labels arranged on a muted blue-green background, casting shadows in direct sunlight.
Brad Jacobs, MD MPH
Clinical Insights
Longevity

Peptides: What’s real, what’s not

From Ozempic to recovery injections to 'longevity' protocols, peptides have quickly moved from niche to mainstream—and the rules governing them are moving just as fast. The promise is compelling: improved metabolism, faster recovery, better energy, longer healthspan. And in some cases, that promise may hold some truth. But before considering peptides, it’s worth slowing down and looking at the full picture, especially when the regulatory landscape is shifting in real time.

What are peptides

Peptides are short chains of amino acids bound together with peptide bonds that act as signaling molecules in the body—think of them as the body’s own messaging system. Proteins are longer chains of the same building blocks.

Peptides help regulate essential functions like:

• metabolism

• inflammation

• hormone activity

• cellular repair

Some peptides are well-studied and widely used in clinical practice. Others are being explored for 'optimization' purposes in generally healthy people—an area of still emerging science.

The science is still catching up

Because peptides originate in the human body, one of the big misconceptions is that they are widely understood and safe by default. They're not.

• Some are supported only by animal data, with limited human experience

• Long-term safety for most peptides remains unknown

• Effects can also vary significantly from person to person

Even widely used peptide-based medications can come with meaningful side effects—enough that a notable percentage of patients discontinue use within the first year. This doesn't make them inherently unsafe, but it does mean they require thoughtful, individualized decision-making.

Know what you're getting

Separate from how peptides work is a more practical question:
Do you know what you’re actually getting?

Many peptides are produced through compounding pharmacies, meaning the ingredients may be FDA-approved, but the compounded product itself is not. This creates variability in:

• quality

• purity

• strength

There have been many documented cases of products containing incorrect or contaminated substances. Overseas manufacturers have even fewer regulatory controls. This is not a flaw of peptides themselves—it's a reflection of a rapidly evolving and uneven regulatory landscape.

Where you source matters. And it will continue to matter however the rules shake out—more on that below.

Where things stand today

The regulatory status of peptides has shifted several times in recent years, and we’re now in the middle of another significant inflection point. Here’s where things stand.

Earlier this year, the FDA moved several previously restricted peptides off the Category 2 restricted list—a first step toward restoring legal compounding access. Then in July, an FDA advisory committee narrowly voted over two days to recommend 6 of 7 proposed peptides for the pharmacy compounding 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. The seventh, Emideltide, didn’t receive the committee’s support.

The 503A Bulks List is the FDA’s roster of bulk drug substances that licensed compounding pharmacies are permitted to use when making customized medications for patients. Getting a peptide onto that list takes three steps:

STEP 1: Category 2 removal
The peptide is taken off the restricted list. This happened in April.

STEP 2: Advisory committee recommendation
A committee reviews the evidence and votes. This happened at the July hearing.

STEP 3: Formal FDA rulemaking
The FDA reviews the recommendation, proposes a rule, takes public comment, and issues a final rule. This has not happened yet.

Only once Step 3 is complete would these peptides be fully legal for compounding pharmacies to produce.

Then on October 28th, HHS Secretary Robert F. Kennedy Jr. announced that his department would not take enforcement action against compounding pharmacies distributing these peptides—even before Step 3 is complete. In practical terms, that means wider access could arrive ahead of formal approval. The policy is interim: a short public comment period closes in mid-November, and HHS can revise or withdraw it if safety or quality problems emerge.

The policy has sparked debate. Making peptides more accessible before the data is fully established raises legitimate safety concerns. Some argue it could also make future restrictions harder to enforce. Others contend it’s the more pragmatic path—that people will find access regardless, and that this approach at least brings compounding pharmacies under higher testing and manufacturing standards: the policy requires a patient-specific prescription, ingredients from FDA-registered suppliers with a certificate of analysis, and reporting of adverse events.

Even with broader access, sourcing remains a live concern. Legal compounding is permitted—not standardized, and not FDA-approved. The pharmacy, the manufacturer, and the oversight behind the product still matter.

One peptide worth slowing down on: TB-500

Of the six peptides heading toward wider access, TB-500 is one we get asked about most. It's a core piece of the "Wolverine stack"—the BPC-157 + TB-500 combo that's become popular online for recovery and healing, with a name promising superhero-level bounce-back. That popularity, combined with how little is actually known, is exactly why it’s worth a closer look. And the new HHS policy covers single-ingredient products only, so a combined BPC-157 + TB-500 product falls outside it.

Here's the core confusion: TB-500 and Thymosin Beta-4 get talked about as if they're the same thing. They're not.

WHAT HAS BEEN STUDIED: Thymosin Beta-4
A full-length protein the body makes naturally, 43 amino acids, with limited early-stage human trials and no FDA approval for any use.

WHAT'S ACTUALLY BEING INJECTED: TB-500
A synthetic fragment built from just the “active region” of Thymosin Beta-4, usually 7 amino acids, with no human studies on the compound itself.

This gap isn’t a small detail. A fragment doesn’t necessarily behave like the whole protein—it can bind differently, break down at another rate, and trigger downstream effects that look nothing like the original. A 2024 study found TB-500 is rapidly broken down into a further metabolite, raising the question of whether the effects people attribute to TB-500 are even coming from TB-500 itself. In other words, we don’t know the mechanism behind “TB-500 worked for me.”

And the not-knowing doesn't stop at how it works. It extends somewhere much more serious. The same signaling pathway that could help with healing—telling cells to migrate and grow new blood vessels—is also how tumors grow and spread. Higher natural levels of Thymosin Beta-4 have been linked to worse cancer outcomes. That's not proof that TB-500 injections cause cancer. But it tells us the signaling pathway the natural protein activates has a real downside in cancer biology—and nobody has checked whether the fragment people inject triggers that same pathway. 

We raise this not to alarm, but because it’s the kind of nuance that gets lost when something becomes popular.

Why this moment feels so accelerated

Interest in peptides has grown quickly, and now policy is moving quickly too. As access expands—through regulatory shifts, enforcement discretion, and growing demand—the category includes everything from clinically validated treatments to promising but early-stage therapies to products that still exist in a regulatory gray zone. All often discussed as if they are the same.

That’s exactly why we don’t treat “it’s a peptide” as a stamp of approval. Every therapy we consider gets evaluated on its own merits—not on the hype surrounding the category, and not on the speed of the regulatory moment.

How we think about it

Before introducing any new therapy, we prioritize:

• Safety

• Quality and sourcing

• Effectiveness

Peptides can be a valuable tool within the right context. But they are not a shortcut—and they're not one-size-fits-all. The right question isn't "Are peptides good or bad?" It's "Is this specific peptide, from this specific source, right for you?" That's a conversation we’re here to have


—
A note from Dr. Brad & Dr. Keith


We’re excited about the potential of peptides, they represent a meaningful frontier in medicine. But just because something is available doesn’t mean it’s appropriate.

In our practice, the decision to use a peptide is never driven by trends. It’s driven by a clear understanding of the individual in front of us—their biology, their goals, and their tolerance for risk. If the foundation isn’t in place—sleep, nutrition, movement, stress—adding peptides won’t create the outcome patients are looking for.

When we do use peptides, we care deeply about where they come from, how they’re made, and how they’re monitored over time.

Done thoughtfully, they can be a powerful tool. Done casually, they introduce unnecessary risk.

Sources
https://www.sciencedirect.com/science/article/pii/S1570023224000412?via%3Dihub
https://www.jpatholtm.org/journal/view.php?doi=10.4132/jptm.2016.08.23
https://aacrjournals.org/mcr/article/16/5/880/268687/Tumor-Progression-Is-Mediated-by-Thymosin-4
https://www.sciencedirect.com/science/article/abs/pii/S034403381730105X
https://abcnews.com/Health/fda-advisers-narrowly-vote-add-6-peptides-drug/story?id=135064915
https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html
https://www.healthaffairs.org/content/forefront/fda-advisory-committee-s-vote-may-open-drug-compounding-back-door-unapproved-peptides
https://www.wsj.com/health/healthcare/rfk-jr-allows-unapproved-peptides-on-the-market-9cf4a6d3
https://www.nytimes.com/2026/10/28/health/peptides-kennedy-fda.html